Literature DB >> 20156065

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.

Zhe Yuan1, Kimberly R Ledesma, Renu Singh, Jingguo Hou, Randall A Prince, Vincent H Tam.   

Abstract

BACKGROUND: Combination antimicrobial therapy is clinically used as a last-resort strategy to control multidrug-resistant bacterial infections. However, selection of antibiotics is often empirical, and conventional assessment of combined drug effect has not been correlated to clinical outcomes. Here, we report a quantitative method to assess combined killing of antimicrobial agents against 2 multidrug-resistant bacteria.
METHODS: Combined time-kill studies were performed using clinically achievable concentrations for each 2-agent combination against clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. Bacterial burden observed at 24 h was mathematically modeled using a 3-dimensional response surface. Subsequently, a neutropenic murine pneumonia model with simulated clinical dosing exposures was used to validate our quantitative assessment of combined killing.
RESULTS: Different antimicrobial combinations were found to have varying efficacy against the multidrug-resistant bacteria. As predicted by our quantitative method, cefepime plus amikacin was found to be the most superior combination, which was evidenced by a reduction in tissue bacterial burden and prolonged survival of infected animals.
CONCLUSIONS: The consistency between the predictions of the mathematical model and in vivo observations substantiated the robustness of our quantitative method. These data highlighted a novel and promising method to guide rational selection of antimicrobial combination in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156065     DOI: 10.1086/651024

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

4.  Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.

Authors:  Dana R Bowers; Henry Cao; Jian Zhou; Kimberly R Ledesma; Dongxu Sun; Olga Lomovskaya; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

Review 5.  Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.

Authors:  Elizabeth B Hirsch; Vincent H Tam
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-08       Impact factor: 2.217

Review 6.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

7.  Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii.

Authors:  Koichi Yamada; Katsunori Yanagihara; Norihito Kaku; Yosuke Harada; Yohei Migiyama; Kentaro Nagaoka; Yoshitomo Morinaga; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Hiroo Hasegawa; Hiroshige Mikamo; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

8.  Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Authors:  Cornelia B Landersdorfer; Rajbharan Yadav; Jürgen B Bulitta; Kate E Rogers; Tae Hwan Kim; Beom Soo Shin; John D Boyce; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

10.  Multistrain models predict sequential multidrug treatment strategies to result in less antimicrobial resistance than combination treatment.

Authors:  Amais Ahmad; Camilla Zachariasen; Lasse Engbo Christiansen; Kaare Græsbøll; Nils Toft; Louise Matthews; John Elmerdahl Olsen; Søren Saxmose Nielsen
Journal:  BMC Microbiol       Date:  2016-06-23       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.